Spyre Therapeutics, Inc. (SYRE)
NASDAQ · Manufacturing · Pharmaceutical preparations
$85.69−$1.40 (−1.61%) on the dayAs of the close; data may be delayed.
SYRE price, last 12 months
Key stats
- Previous close
- $87.09
- Open
- $87.09
- Day range
- $85.63 – $88.10
- 52-week range
- $15.49 – $110.18
- Volume
- 369.9K
- Avg volume (20 days)
- 1.3M
- Market cap
- $7.6B
Performance
1W−5.1%
1M−8.5%
3M−2.5%
6M+80.3%
YTD+161.6%
1Y+404.1%
vs S&P 500, 1Y+387.3 pts
Technicals and fundamentals
About Spyre Therapeutics, Inc.
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $7.6B